Phase II study of lapatinib and tegafur combination efficacy for the treatment of HER2+metastatic breast cancer.

被引：0
|
作者：
Manikhas, Alexey
Sharvashidze, Ineza O.
Kotkova, Tatjana N.
机构：
[1] City Clin Oncol Dispensary, St Petersburg, Russia
[2] State Clin Oncol Dispensary, St Petersburg, Russia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11086
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase 3 study of maintenance treatment of tucatinib or placebo in combination with trastuzumab and pertuzumab in HER2+metastatic breast cancer (HER2CLIMB-05, trial in progress)
    Muller, V
    Hamilton, E.
    O 'Sullivan, C.
    Martin, M.
    Sohn, J.
    Tryfonidis, K.
    Santarpia, L.
    Yang, S.
    Dieras, V
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 106 - 106
  • [42] Phase II clinical study of lapatinib (GW572016) in patients with advanced or metastatic breast cancer.
    Iwata, H.
    Toi, M.
    Fujiwara, Y.
    Ito, Y.
    Fujii, H.
    Nakamura, S.
    Aogi, K.
    Zaks, T.
    Sasaki, Y.
    Takashima, S.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S68 - S68
  • [43] Evolving perspectives on the treatment of HR+/HER2+metastatic breast cancer
    Pegram, Mark
    Pietras, Richard
    Dang, Chau T.
    Murthy, Rashmi
    Bachelot, Thomas
    Janni, Wolfgang
    Sharma, Priyanka
    Hamilton, Erika
    Saura, Cristina
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [44] A phase II study with lead-in safety cohort of cabazitaxel (C) plus lapatinib (L) as therapy for HER2+metastatic breast cancer (MBC) with intracranial metastases (mets)
    Yardley, Denise A.
    Hainsworth, John D.
    Hamilton, Erika Paige
    Hart, Lowell L.
    Shastry, Mythili
    DeBusk, Laura M.
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [45] A feasibility study of combination therapy with trastuzumab (T), cyclophosphamide (CY), and an allogeneic GM-CSF-secreting breast tumor vaccine for the treatment of HER2+metastatic breast cancer.
    Emens, L. A.
    Gupta, R.
    Petrik, S.
    Laiko, M.
    Leatherman, J. M.
    Levi, J.
    Asquith, J. M.
    Daphtary, M. M.
    Garrett-Mayer, E.
    Kobrin, B. J.
    Davidson, N. E.
    Dauses, T.
    Atay-Rosenthal, S.
    Ye, X.
    Wolff, A. C.
    Stearns, V.
    Jaffee, E. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [46] The role of tyrosine kinase inhibitors in the treatment of HER2+metastatic breast cancer
    Le Du, Fanny
    Dieras, Veronqiue
    Curigliano, Giuseppe
    EUROPEAN JOURNAL OF CANCER, 2021, 154 : 175 - 189
  • [47] Real-world treatment in patients with HER2+metastatic breast cancer
    Colomer, R.
    Hall, P.
    Szkultecka-Debek, M.
    Bondi, R. C.
    Flinois, A.
    Auziere, S.
    Le Cleac'h, J. Y.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (01) : 197 - 205
  • [48] Duration of lapatinib (L)-based therapy in HER2+metastatic breast cancer (MBC) in a single institution.
    Morales, Serafin
    Cud''s, Ariadna Gasol
    Salud, Antonia
    Aguirre Ortega, Elena Maria
    Derabrain, Noema A. Tuset
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [49] Phase II study of lapatinib in combination with vinorelbine in patients with ErbB2-amplified recurrent or metastatic breast cancer
    Saip, P.
    Eralp, Y.
    Ozkan, M.
    Karaca, H.
    Benekli, M.
    Cetin, B.
    Isikdogan, A.
    Kucukoner, M.
    Basaran, G.
    Sen, F.
    Un, O.
    Onur, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [50] Lapatinib in combination with paclitaxel for the treatment of patients with metastatic breast cancer whose tumors overexpress HER2
    Giordano, Sara B.
    Kaklamani, Virginia
    BREAST CANCER MANAGEMENT, 2013, 2 (06) : 529 - 535
12345